Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial -

- Closed a public offering on May 8, 2025, raising the Company’s cash balance and extending its cash runway into the first quarter of 2026 -

Read more at globenewswire.com